check_circleStudy Completed

Bone Metastases, Castration-Resistant Prostate Cancer

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Trial purpose

The main purpose of this study is to establish a recommended dose of Alpharadin to be used in combination with docetaxel in patients with bone metastases from castration-resistant prostate cancer and to investigate safety and explore efficacy of the recommended dose.

Key Participants Requirements

Sex

Male

Age

18 - N/A

Trial summary

Enrollment Goal
63
Trial Dates
July 2010 - June 2015
Phase
Phase 1/Phase 2
Could I Receive a placebo
No
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
New York, 10065, United States
Completed
Baltimore, 21287, United States
Completed
Boston, 02115-6013, United States
Completed
Evanston, 60201, United States
Completed
Seattle, 98109, United States
Completed
San Francisco, 94115, United States
Completed
VILLEJUIF CEDEX, 94805, France

Primary Outcome

  • Dose-escalation: Assessment of dose-limiting toxicities
    date_rangeTime Frame:
    When 6 weeks post-injection data are available for the first combined injection of Alpharadin/docetaxel
    enhanced_encryption
    Safety Issue:
    Yes
  • Expanded safety cohort: Safety of combining Alpharadin with docetaxel (incidence and severity of adverse events and serious adverse events, changes from baseline in laboratory variables, vital signs and physical examination)
    date_rangeTime Frame:
    12 months
    enhanced_encryption
    Safety Issue:
    Yes

Secondary Outcome

  • Signs of long-term radiation toxicity: incidence of manifestations of potential late toxicity, such as new primary cancers and bone marrow changes (acute myelogenous leukaemia, myelodysplastic syndrome, and aplastic anaemia)
    date_rangeTime Frame:
    12 months
    enhanced_encryption
    Safety Issue:
    Yes
  • Exploratory efficacy measurements of Alpharadin in combination with docetaxel versus docetaxel alone such as changes in bone markers, PSA and CTC, time to progression and overall survival
    date_rangeTime Frame:
    12 months
    enhanced_encryption
    Safety Issue:
    No
  • Exploratory patient self-reporting of pain intensity
    date_rangeTime Frame:
    12 months
    enhanced_encryption
    Safety Issue:
    Yes

Trial design

A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Randomized
Blinding
Open Label
Assignment
Parallel Assignment
Trial Arms
2